We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

    • Massachusetts General Hospital

    Health

    Study Shows Pitavastatin Can Prevent Cancer Development in Cases of Chronic Inflammation

    Discover how the drug pitavastatin can effectively prevent cancer development in cases of chronic inflammation by blocking interleukin 33 (IL-33) expression. The study reveals the role of IL-33 in cancer-prone chronic inflammation and the ability of pitavastatin to inhibit IL-33 expression through the mevalonate pathway. Learn how this research highlights the potential of statins, like pitavastatin, as a safe and effective strategy for preventing cancer-related consequences of chronic inflammation.

    Posted on Jhon
    Health

    The Legacy of Richard ‘Rick’ Slayman: First Man to Receive Pig Kidney Transplant

    Discover the groundbreaking story of Richard ‘Rick’ Slayman, the first man to undergo a genetically modified pig kidney transplant. Despite his passing, his journey offers hope and inspiration for the future of xenotransplantation and the potential of genetically modified animals in organ transplants.

    Posted on Jhon
    Health

    Man Discharged After Receiving Genetically Modified Pig Kidney Transplant

    The first man to receive a genetically modified pig kidney transplant has been discharged from Massachusetts General Hospital after a successful surgery. The historic procedure is being celebrated as a significant milestone in the field of transplantation, offering hope to thousands of people in need of transplants. The pig kidney, modified by eGenesis, was approved for use under a compassionate use protocol, potentially addressing the world’s organ shortage.

    Posted on Jhon
    Health

    Man recovering well after receiving genetically modified pig kidney

    62-year-old Rick Slayman received a genetically modified pig kidney in a pioneering transplant surgery, marking a major milestone in organ availability. With a chronic shortage of human donor organs, animal donors may provide hope for thousands in need of transplants. The special pig kidney was provided by eGenesis of Cambridge, Massachusetts, and Mr. Slayman’s recovery is being closely monitored as he continues to take anti-rejection drugs.

    Posted on Jhon